OBMP Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products...

Stats
Šios dienos apimtis	58 992.00
Vidutinė apimtis	8 379.00
Rinkos kapitalizacija	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2020-09-24	Chilcott, Iii Thomas E.	Buy	0
2020-06-05	Ruxin Michael I	Buy	0
2020-05-07	Head Jonathan Frederick	Buy	166 667	Shares of Common Stock
2019-04-24	Holcomb Robert Neal	Buy	3 000 000	Employee Stock Option (right to buy)
2019-04-24	Hoverman Daniel S.	Buy	3 000 000	Employee Stock Option (right to buy)

INSIDER POWER
0.00
Last 25 transactions
Buy: 69 901 401 \| Sell: 14 397 245

Theralink Technologies, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Theralink Technologies, Finansinės ataskaitos

Annual	2021
Pajamos:	$505 604
Bruto pelnas:	$388 148 (76.77 %)
EPS:	$-0.00124

FY	2021
Pajamos:	$505 604
Bruto pelnas:	$388 148 (76.77 %)
EPS:	$-0.00124

FY	2020
Pajamos:	$181 229
Bruto pelnas:	$128 642 (70.98 %)
EPS:	$-0.0374

FY	2019
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-19.00

Financial Reports:

No articles found.

Theralink Technologies,

Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.